Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0N2IE
|
|||
| Former ID |
DNCL003696
|
|||
| Drug Name |
VB-201
|
|||
| Indication | Arteriosclerosis [ICD-11: BD40; ICD-10: I70] | Phase 2 | [1] | |
| Psoriasis vulgaris [ICD-11: EA90; ICD-9: 696] | Phase 2 | [2] | ||
| Company |
VBL Therapeutics
|
|||
| Structure |
 |
Download2D MOL
|
||
| Formula |
C29H60NO8P
|
|||
| Canonical SMILES |
CCCCCCCCCCCCCCCCOCC(COP(=O)([O-])OCC[N+](C)(C)C)OCCCCC(=O)O
|
|||
| InChI |
1S/C29H60NO8P/c1-5-6-7-8-9-10-11-12-13-14-15-16-17-19-23-35-26-28(36-24-20-18-21-29(31)32)27-38-39(33,34)37-25-22-30(2,3)4/h28H,5-27H2,1-4H3,(H-,31,32,33,34)/t28-/m1/s1
|
|||
| InChIKey |
JGGNOCUEWOGWPL-MUUNZHRXSA-N
|
|||
| CAS Number |
CAS 630112-41-3
|
|||
| PubChem Compound ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | VB-201, an oxidized phospholipid small molecule, inhibits CD14- and Toll-like receptor-2-dependent innate cell activation and constrains atherosclerosis. Clin Exp Immunol. 2014 Jan;175(1):126-37. | |||
| REF 2 | ClinicalTrials.gov (NCT01001468) Study to Assess VB-201 in Patients With Psoriasis. U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.